Excessive Catecholamine Secretion and the Activation of the Renin-Angiotensin-Aldosterone-System in Patients with Pheochromocytoma: A Single Center Experience and Overview of the Literature

Abstract

Catecholamines stimulate renin-secretion in the juxtaglomerular cells of the kidney and a number of case reports suggest an association between pheochromocytoma and activation of the RAAS. Therefore, it could be asked whether patients suffering from pheochromocytoma with high concentrations of circulating catecholamines present with oversecretion of renin and aldosterone. We identified twelve patients with excessive catecholamine secretion due to pheochromocytoma and compared them to a group of twelve patients with essential hypertension (EH) with regard to the activation of the renin-angiotensin-aldosterone-system (RAAS). The PubMed database was screened for studies that investigate the association between pheochromocytoma and activation of the RAAS. The plasma concentrations of metanephrines (19.9-fold) and normetanephrines (29.5-fold) were significantly higher in the pheochromocytoma group than in the EH group. Renin and aldosterone levels were 1.3-fold and 1.6-fold higher, respectively, as compared to the EH group, whereas the differences were not statistically significant. There was no significant correlation between plasma metanephrine or normetanephrine levels and the plasma renin concentration (r_s=0.077, r_s=0.049, respectively) in our patients. The data from our institution and from review of literature suggest that an association between pheochromocytoma in the context of high plasma catecholamine levels and activation of the RAAS is present. However, results have not been consistent. Thus, other causes of RAAS-activation should be considered also in the presence of pheochromocytoma or reinvestigation for aldosteronism should be offered to such patients after removal of the catecholamine-producing tumour.

Key words

secondary aldosteronism - renin - aldosterone - pheochromocytoma - catecholamines - metanephrine - normetanephrine

• References

• 1 Beierwaltes WH. The role of calcium in the regulation of renin secretion. Am J Physiol Renal Physiol 2010; 298: F1-F11
• 2 Molinoff PB. Alpha- and beta-adrenergic receptor subtypes properties, distribution and regulation. Drugs 1984; 28 (Suppl. 02) 1-15
• 3 Viola A, Monticone S, Burrello J, Buffolo F, Lucchiari M, Rabbia F, Williams TA, Veglio F, Mengozzi G, Mulatero P. Renin and aldosterone measurements in the management of arterial hypertension. Horm Metab Res 2015; 47: 418-426
• 4 Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young Jr. WF. The management of primary aldosteronism: case detection, diagnosis, and treatment: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916
• 5 Blondin D, Quack I, Haase M, Kücükköylü S, Willenberg HS. Indication and technical aspects of adrenal blood sampling. Rofo 2015; 187: 19-28
• 6 Song AL, Zeng ZP, Tong AL, Lu L, Chen S, Li M, Fu CL, Wang YH, Sun ML. Differences of blood plasma renin activity, angiotensin II and aldosterone levels in essential or secondary hypertension. Zhonghua Nei Ke Za Zhi 2012; 51: 294-298
• 7 Bernini M, Bacca A, Casto G, Carli V, Cupisti A, Carrara D, Farnesi I, Barsotti G, Naccarato AG, Bernini G. A case of pheochromocytoma presenting as secondary hyperaldosteronism, hyperparathyroidism, diabetes and proteinuric renal disease. Nephrol Dial Transplant 2011; 26: 1104-1107
• 8 Stoicescu M, Csepento C, Mutiu G, Bungau S. The role of increased plasmatic renin level in the pathogenesis of arterial hypertension in young adults. Rom J Morphol Embryol 2011; 52: 419-423
• 9 Zacharieva S, Atanassova I, Orbetzova M, Nachev E, Kalinov K, Kirilov G, Shigarminova R, Ivanova R, Dashev G. Circulating vascular endothelial growth factor and active renin concentrations and prostaglandin E2 urinary excretion in patients with adrenal tumours. Eur J Endocrinol 2004; 150: 345-349
• 10 Paniagua R, Rodriguez E, Amato D, Sanchez G, Ron O, Rodriguez F, Herrera-Acosta J. Response of atrial natriuretic factor to acute extracellular fluid volume in patients with pheochromocytoma. Arch Med Res 2000; 31: 613-617
• 11 Tseng FY, Chang CC, Peng WJ, Chan KC, Chang SL, Chang TC, Lai MK, Huang SH, Shun CT. A case of extraadrenal pheochromocytoma associated with adrenal cortical nodular hyperplasia and papillary thyroid carcinoma. Endocr J 1999; 46: 35-41
• 12 Coruzzi P, Musiari L, Biggi A, Mossini GL, Novarini A. Renin-angiotensin system unresponsiveness in phaeochromocytoma. J Hum Hypertens 1992; 6: 239-241
• 13 Lenz T, Thiede HM, Nussberger J, Atlas SA, Distler A, Schulte KL. Hyperreninemia and secondary hyperaldosteronism in a patient with pheochromocytoma and von Hippel-Lindau disease. Nephron 1992; 62: 345-350
• 14 Rechavia E, Mager A, Sagie A, Strasberg B, Sclarovsky S. Prazosin's effect in high renin hypertension complicating pheochromocytoma. Clin Cardiol 1991; 14: 533-535
• 15 Deal JE, Sever PS, Barratt TM, Dillon MJ. Phaeochromocytoma–investigation and management of 10 cases. Arch Dis Child 1990; 65: 269-274
• 16 Yakovlev GM, Yakovlev VA, Trofimov VM, Krasnov LM, Shustov SB. Interrelation between hemodynamic parameters and the functional state of components of the endocrine system in patients with pheochromocytoma. Ter Arkh 1990; 62: 95-98
• 17 Plouin PF, Chatellier G, Rougeot MA, Comoy E, Menard J, Corvol P. Plasma renin activity in phaeochromocytoma: Effects of beta-blockade and converting enzyme inhibition. J Hypertens 1988; 6: 579-585
• 18 Tulassay T, Verebely T, Szucs L, Rascher W, Jellinek K, Reusz G, Miltenyi M, Nagy I. Vasoactive hormones in familial pheochromocytoma with predominant norepinephrine secretion. Child Nephrol Urol 1988; 9: 228-231
• 19 Potapova GN, Sokolova RI, Arabidze GG, Kazeev KN, Kazanchian PO. Residual hypertension after removal of a pheochromocytoma (morphologic study of the kidneys). Kardiologiia 1987; 27: 13-18
• 20 Richards AM, Nicholls MG, Espiner EA, Ikram H, Hamilton E, Maslowski AH. Arterial pressure and hormone relationships in phaeochromocytoma. J Hypertens 1983; 1: 373-379
• 21 Muratani H, Kawasaki T, Kawano Y, Abe I, Kumamoto K, Omae T. Activation of renin-angiotensin system in maintenance of high blood pressure in uncomplicated pheochromocytoma–a case report. Jpn J Med 1983; 22: 227-230
• 22 Bravo EL. Effects of clonidine on sympathetic function. Chest 1983; 83: 369-371
• 23 Ganguly A, Weinberger MH, Grim CE. The renin-angiotensin-aldosterone system in Cushing's syndrome and pheochromocytoma. Horm Res 1983; 17: 1-10
• 24 Rockel A, Heidland A. Saralasin in resistant hypertensive crisis (author's transl). Med Klin 1979; 74: 401-407
• 25 Hung W, August GP. Hyperreninemia and secondary hyperaldosteronism in pheochromocytomas. J Pediatr 1979; 94: 215-217
• 26 Decoulx M, Lefebvre J, Cappoen JP, Racadot A, Linquette M. Phaeochromocytoma with hypokalaemia (two cases) (author's transl). Ann Endocrinol (Paris) 1978; 39: 171-177
• 27 Passwell J, Boichis H, Lotan D, David R, Theodor R, Cohen BE, Many M. The metabolic effects of excess noradrenaline secretion from a pheochromocytoma. Am J Dis Child 1977; 131: 1011-1014
• 28 Menage JJ, Loubrieu G, Besnard JC, Neel JL. Renin plasmatic activity and plasma aldosterone in three cases of pheochromocytoma (author's transl). Ann Endocrinol (Paris) 1977; 38: 161-162
• 29 Wilkins GE, Schmidt N, Lee-Son L. Coexistence of pheochromocytoma, adrenal adenoma and hypokalemia. Can Med Assoc J 1977; 116: 360-362
• 30 Munk Z, Tolis G, Jones W, Fallen E, McLean P. Pheochromocytoma presenting with pulmonary edema and hyperamylasemia. Can Med Assoc J 1977; 116: 357-359
• 31 van Hoogdalem P, Donker AJ, Brentjens JR, van der Hem GK, Oosterhuis JW. Partial correction of hypertension by angiotensin II blockade in a patient with phaeochromocytoma. Acta Med Scand 1977; 201: 395-399
• 32 Horky K, Kopecka J, Greogorova I, Dvorakova J. Relationship between plasma renin activity and urinary catecholamines in various types of hypertension. Endokrinologie 1976; 67: 331-342
• 33 Vetter W, Zaruba K, Armbruster H, Beckerhoff R, Uhlschmid G, Furrer J, Siegenthaler W. Control of plasma aldosterone in terminal renal failure before and after nephrectomy and after renal transplantation. Clin Nephrol 1976; 6: 433-436
• 34 Goodman JR, Roberts JA. The unexpected pheochromocytoma. South Med J 1976; 69: 374-376
• 35 Kitajima W, Saruta T, Kondo K, Yamada R, Aoki S, Nagakubo I. A case of secondary aldosteronism induced by pheochromocytoma. J Urol 1975; 114: 141-143
• 36 Werning C, Ziegler WH, Baumann K, Endres P, Gysling E, Weidmann P, Siegenthaler W. Plasma renin activity in pheochromocytoma. Dtsch Med Wochenschr 1970; 95: 117-118
• 37 Roden M, Raffesberg W, Raber W, Bernroider E, Niederle B, Waldhausl W, Gasic S. Quantification of unconjugated metanephrines in human plasma without interference by acetaminophen. Clin Chem 2001; 47: 1061-1067
• 38 Ezzahti M, Moelker A, Friesema EC, van der Linde NA, Krestin GP, van den Meiracker AH. Blood pressure and neurohormonal responses to renal nerve ablation in treatment-resistant hypertension. J Hypertens 2014; 32: 135-141
• 39 Gill IS, Meraney AM, Bravo EL, Novick AC. Pheochromocytoma coexisting with renal artery lesions. J Urol 2000; 164: 296-301
• 40 Castrop H, Hocherl K, Kurtz A, Schweda F, Todorov V, Wagner C. Physiology of kidney renin. Physiol Rev 2010; 90: 607-673